70 related articles for article (PubMed ID: 20831865)
1. Re: Post-treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate metastatic prostate cancer from localized disease.
Zhu Y; Ye D
Clin Chim Acta; 2010 Dec; 411(23-24):2117. PubMed ID: 20831865
[No Abstract] [Full Text] [Related]
2. Post-treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate metastatic prostate cancer from localized disease.
Deligezer U; Yaman F; Darendeliler E; Dizdar Y; Holdenrieder S; Kovancilar M; Dalay N
Clin Chim Acta; 2010 Oct; 411(19-20):1452-6. PubMed ID: 20573596
[TBL] [Abstract][Full Text] [Related]
3. Global histone H3K27 methylation levels are different in localized and metastatic prostate cancer.
Ellinger J; Kahl P; von der Gathen J; Heukamp LC; Gütgemann I; Walter B; Hofstädter F; Bastian PJ; von Ruecker A; Müller SC; Rogenhofer S
Cancer Invest; 2012 Feb; 30(2):92-7. PubMed ID: 22149091
[TBL] [Abstract][Full Text] [Related]
4. The use of real-time reverse transcription-PCR for prostate-specific antigen mRNA to discriminate between blood samples from healthy volunteers and from patients with metastatic prostate cancer.
Patel K; Whelan PJ; Prescott S; Brownhill SC; Johnston CF; Selby PJ; Burchill SA
Clin Cancer Res; 2004 Nov; 10(22):7511-9. PubMed ID: 15569981
[TBL] [Abstract][Full Text] [Related]
5. JMJD3 is a histone H3K27 demethylase.
Xiang Y; Zhu Z; Han G; Lin H; Xu L; Chen CD
Cell Res; 2007 Oct; 17(10):850-7. PubMed ID: 17923864
[TBL] [Abstract][Full Text] [Related]
6. Cancer: a changing global view.
Marte B
Nature; 2005 Jun; 435(7046):1172. PubMed ID: 15988507
[No Abstract] [Full Text] [Related]
7. [RT-PCR assay for detecting PSA mRNA in peripheral blood of prostate cancer patients].
Okubo Y; Ito T
Hinyokika Kiyo; 1999 Jan; 45(1):25-30. PubMed ID: 10086262
[TBL] [Abstract][Full Text] [Related]
8. Immunolocalization and messenger RNA expression of bone morphogenetic protein-6 in human benign and malignant prostatic tissue.
Hamdy FC; Autzen P; Robinson MC; Horne CH; Neal DE; Robson CN
Cancer Res; 1997 Oct; 57(19):4427-31. PubMed ID: 9331107
[TBL] [Abstract][Full Text] [Related]
9. Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer.
Masuda H; Fukabori Y; Nakano K; Takezawa Y; CSuzuki T; Yamanaka H
Prostate; 2003 Mar; 54(4):268-74. PubMed ID: 12539225
[TBL] [Abstract][Full Text] [Related]
10. Global histone modification patterns predict risk of prostate cancer recurrence.
Seligson DB; Horvath S; Shi T; Yu H; Tze S; Grunstein M; Kurdistani SK
Nature; 2005 Jun; 435(7046):1262-6. PubMed ID: 15988529
[TBL] [Abstract][Full Text] [Related]
11. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.
Feeley BT; Gamradt SC; Hsu WK; Liu N; Krenek L; Robbins P; Huard J; Lieberman JR
J Bone Miner Res; 2005 Dec; 20(12):2189-99. PubMed ID: 16294272
[TBL] [Abstract][Full Text] [Related]
12. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome.
Yu J; Yu J; Rhodes DR; Tomlins SA; Cao X; Chen G; Mehra R; Wang X; Ghosh D; Shah RB; Varambally S; Pienta KJ; Chinnaiyan AM
Cancer Res; 2007 Nov; 67(22):10657-63. PubMed ID: 18006806
[TBL] [Abstract][Full Text] [Related]
13. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Kaplan PJ; Mohan S; Cohen P; Foster BA; Greenberg NM
Cancer Res; 1999 May; 59(9):2203-9. PubMed ID: 10232609
[TBL] [Abstract][Full Text] [Related]
14. Androgen regulated TRPM8 expression: a potential mRNA marker for metastatic prostate cancer detection in body fluids.
Bai VU; Murthy S; Chinnakannu K; Muhletaler F; Tejwani S; Barrack ER; Kim SH; Menon M; Veer Reddy GP
Int J Oncol; 2010 Feb; 36(2):443-50. PubMed ID: 20043080
[TBL] [Abstract][Full Text] [Related]
15. Functional Loss of the gamma-catenin gene through epigenetic and genetic pathways in human prostate cancer.
Shiina H; Breault JE; Basset WW; Enokida H; Urakami S; Li LC; Okino ST; Deguchi M; Kaneuchi M; Terashima M; Yoneda T; Shigeno K; Carroll PR; Igawa M; Dahiya R
Cancer Res; 2005 Mar; 65(6):2130-8. PubMed ID: 15781623
[TBL] [Abstract][Full Text] [Related]
16. [Expression of Smad4 in prostate cancer LNCaP and ARCaP cell lines with different metastatic potentials and its significance].
Wu KJ; Zhang D; Zhu GF; Cheng HP; Zeng J; Zhang LL; Wang XY; He DL
Zhonghua Nan Ke Xue; 2009 Jan; 15(1):41-4. PubMed ID: 19288748
[TBL] [Abstract][Full Text] [Related]
17. Reliability of PSA circulating cells as markers of metastatic prostate cancer.
Cardillo MR; Di Silverio F; Gentile V
Scand J Clin Lab Invest; 2004; 64(7):687-89. PubMed ID: 15513326
[No Abstract] [Full Text] [Related]
18. Epigenetic regulation of human bone morphogenetic protein 6 gene expression in prostate cancer.
Tamada H; Kitazawa R; Gohji K; Kitazawa S
J Bone Miner Res; 2001 Mar; 16(3):487-96. PubMed ID: 11277266
[TBL] [Abstract][Full Text] [Related]
19. Unmethylated E-cadherin gene expression is significantly associated with metastatic human prostate cancer cells in bone.
Saha B; Kaur P; Tsao-Wei D; Naritoku WY; Groshen S; Datar RH; Jones LW; Imam SA
Prostate; 2008 Nov; 68(15):1681-8. PubMed ID: 18712716
[TBL] [Abstract][Full Text] [Related]
20. Expression of bone morphogenetic protein-7 (BMP-7) in human prostate.
Masuda H; Fukabori Y; Nakano K; Shimizu N; Yamanaka H
Prostate; 2004 Apr; 59(1):101-6. PubMed ID: 14991870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
